Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

17-trifluoromethylphenyl trinor prostaglandin F2α (17-CF3PTPGF2α) was reported recently to exhibit in vitro and in vivo anticancer activity. Based solely on the results of in silico molecular docking, it was claimed that this compound is NK1 receptor (NK1R) antagonist and that its activity is through this receptor. In this contribution we show that 17-CF3PTPGF2α is only a very weak NK1R ligand (IC50 > 200 μM). In connection with that we discuss the issue of this compound's molecular target. Finally, we briefly narrate on the proper use of molecular docking in biomedical research. Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.


Joanna Matalińska, Piotr F J Lipiński. Docking is not enough: 17-trifluoromethylphenyl trinor PGF2α is only a very weak ligand of neurokinin-1 receptor. Experimental and molecular pathology. 2023 Feb;129:104849

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 36526011

View Full Text